EMA confirms suspension or restriction of quinolone and fluoroquinolone antibiotics
The marketing authorisation of medicines containing cinoxacin, flumequine, nalidixic acid and pipemidic acid should be suspended and the use of the remaining fluoroquinolone antibiotics restricted, the European Medicines Agency has concluded following a 21-month review.…